Compare KALU & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALU | IDYA |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2006 | 2019 |
| Metric | KALU | IDYA |
|---|---|---|
| Price | $171.16 | $37.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $147.33 | $52.86 |
| AVG Volume (30 Days) | 270.9K | ★ 1.6M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | ★ 135.89 | 61.90 |
| EPS | ★ 3.71 | N/A |
| Revenue | ★ $1,585,900,000.00 | $218,710,000.00 |
| Revenue This Year | $13.37 | N/A |
| Revenue Next Year | $2.62 | $201.05 |
| P/E Ratio | $47.51 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $71.44 | $21.33 |
| 52 Week High | $195.96 | $39.28 |
| Indicator | KALU | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 71.16 |
| Support Level | $171.42 | $29.51 |
| Resistance Level | $181.47 | $38.17 |
| Average True Range (ATR) | 8.43 | 1.68 |
| MACD | -0.67 | 0.55 |
| Stochastic Oscillator | 26.45 | 93.98 |
Kaiser Aluminum Corp specializes in the production of semi-fabricated specialty aluminum mill products, such as aluminum plate and sheet, bare and coated coil and extruded and drawn products, for the end market applications: Aero/HS Products; Packaging; GE Products; and Automotive Extrusions. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.